Mayfield Heights, OH, United States of America

Nicholas DeLucia

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Oakwood Laboratories LLC. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Nicholas DeLucia

Introduction

Nicholas DeLucia is an accomplished inventor based in Mayfield Heights, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of extended-release formulations. His innovative work has the potential to improve patient outcomes through more effective medication delivery.

Latest Patents

Nicholas DeLucia holds a patent for "Microsphere formulations comprising lurasidone and methods for making and using the same." This patent describes extended-release microsphere formulations that allow for the release of lurasidone in vivo over a period of about 30 days. This advancement in drug formulation can enhance the therapeutic effects of lurasidone, providing a more consistent and prolonged release of the medication.

Career Highlights

DeLucia is currently associated with Oakwood Laboratories LLC, where he continues to innovate in the pharmaceutical sector. His work focuses on developing formulations that can significantly impact the way medications are administered and absorbed by patients.

Collaborations

Some of his notable coworkers include Colin Spencer and Griffin Beyer, who contribute to the collaborative environment at Oakwood Laboratories LLC. Their combined expertise fosters a culture of innovation and excellence in pharmaceutical development.

Conclusion

Nicholas DeLucia's contributions to the field of pharmaceuticals through his innovative patent on microsphere formulations exemplify the importance of research and development in improving medication delivery systems. His work continues to pave the way for advancements in patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…